Transcelline Information

We believe that Anti-retroviral (ARV) therapy is an essential tool in waging the war against HIV/AIDS. Hence, we have taken a conscious decision to manufacture and supply affordable, high quality generic ARV treatments to patients around the world. We offer today a wide range of World Health Organisation prequalified (WHO PQ) ARV products that are supplied in over 90 countries in Africa, Latin America, CIS and Asia. We estimate currently close to a million patients worldwide use our ARV products for their daily treatment needs. We have been associated with this cause since 2001 offering ARVs to various National AIDS treatment programmes in Africa. We were also responsible for making these drugs affordable in order to improve access. In 2004, the Clinton Health Access Initiative (CHAI) was signed up with a view to reducing the cost of the triple drug cocktail for consortium partners in Africa and other countries. As a trusted name in affordable medicines, we take pride in our ARVs being sourced for various large treatment programmes by major institutions, Indeed, with pharmaceuticals for several first-line and second line Highly Active Anti-retroviral Therapy (HAART) regimens and a portfolio providing a large range of bio-equivalent generic ARVs, we hope to contribute significantly to combating HIV/AIDS.